Ochratoxin A carcinogenicity involves a complex network of epigenetic mechanisms

Toxicon

Volumn 52, Issue 2, 2008, Pages 195-202

  Marin Kuan, Maricel ^a   Cavin, Christophe ^a   Delatour, Thierry ^a   Schilter, Benoît ^a  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Carcinogenicity; Cell signalling; Epigenetic; Mechanism of action; Nephrotoxicity; Ochratoxin A; Risk assessment

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 4ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OCHRATOXIN;

CALCIUM HOMEOSTASIS; CARCINOGENICITY; ENZYME ACTIVATION; EPIGENETICS; GENE EXPRESSION; GENOTOXICITY; HUMAN; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; FOOD MICROBIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MYCOTOXINS; OCHRATOXINS; RISK ASSESSMENT; TOXICOGENETICS;

ANIMALIA;

EID: 49649099057     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2008.04.166     Document Type: Review

References (82)

1. Al Anati L., and Petzinger E. Immunotoxic activity of ochratoxin A. J. Vet. Pharmacol. Ther. 29 2 (2006) 79-90
2. Arbillaga L., Azqueta A., Ezpeleta O., and Lopez D.C. Oxidative DNA damage induced by ochratoxin A in the HK-2 human kidney cell line: evidence of the relationship with cytotoxicity. Mutagenesis 22 1 (2007) 35-42
3. Baudrimont I., Betbeder A.M., Gharbi A., Pfohl-Leszkowicz A., Dirheimer G., and Creppy E.E. Effect of superoxide dismutase and catalase on the nephrotoxicity induced by subchronical administration of ochratoxin A in rats. Toxicology 89 2 (1994) 101-111
4. Benesic A., Mildenberger S., and Gekle M. Nephritogenic ochratoxin A interferes with hormonal signalling in immortalized human kidney epithelial cells. Pflugers Arch. 439 3 (2000) 278-287
5. Cavin C., Delatour T., Marin-Kuan M., Holzhauser D., Higgins L., Bezencon C., Guignard G., Junod S., Piguet D., Richoz-Payot J., Gremaux E., Hayes J.D., Nestler S., Mantle P., and Schilter B. Reduction in antioxidant defences may contribute to ochratoxin A toxicity and carcinogenicity. Toxicol. Sci. 96 1 (2007) 30-39
6. Cheung C.W., Vesey D.A., Nicol D.L., and Johnson D.W. The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation. Kidney Int. 65 4 (2004) 1272-1279
7. Chong X., and Rahimtula A.D. Alterations in ATP-dependent calcium uptake by rat renal cortex microsomes following ochratoxin A administration in vivo or addition in vitro. Biochem. Pharmacol. 44 7 (1992) 1401-1409
8. Clark H.A., and Snedeker S.M. Ochratoxin A: its cancer risk and potential for exposure. J. Toxicol. Environ. Health B Crit. Rev. 9 (2006) 265-296
9. Codina A., Love J.D., Li Y., Lazar M.A., Neuhaus D., and Schwabe J.W. Structural insights into the interaction and activation of histone deacetylase 3 by nuclear receptor corepressors. Proc. Natl. Acad. Sci. U.S.A. 102 17 (2005) 6009-6014
10. Creppy E.E., Baudrimont I., Belmadani A., and Betbeder A.M. Aspartame as a preventive agent of chronic toxic effects of ochratoxin A in experimental animals. Food Addit. Contam. 13 Suppl. (1996) 51-52
11. Delatour, T., Mally, A., Richoz, J., Oezden, S., Dekant, W., Ihmels, H., Otto, D., Gasparutto, D., Marin-Kuan, M., Schilter, B., Cavin, C., 2008. Absence of 2′-deoxyguanosine-carbon 8-bound ochratoxin A adduct in rat kidney DNA monitored by isotope dilution LC-MS/MS. Mol. Nutr. Food Res. 52, 472-482.
12. Dai J., Park G., Wright M.W., Adams M., Akman S.A., and Manderville R.A. Detection and characterization of a glutathione conjugate of ochratoxin A. Chem. Res. Toxicol. 15 12 (2002) 1581-1588
13. Dirheimer G., and Creppy E.E. Mechanism of action of ochratoxin A. IARC Sci. Publ. 115 (1991) 171-186
14. Dong J., Everitt J.I., Lau S.S., and Monks T.J. Induction of ERK1/2 and histone H3 phosphorylation within the outer stripe of the outer medulla of the Eker rat by 2,3,5-tris-(glutathion-S-yl)hydroquinone. Toxicol. Sci. 80 2 (2004) 350-357
15. Eder S., Benesic A., Freudinger R., Engert J., Schwerdt G., Drumm K., and Gekle M. Nephritogenic ochratoxin A interferes with mitochondrial function and pH homeostasis in immortalized human kidney epithelial cells. Pflugers Arch. 440 4 (2000) 521-529
16. EFSA, 2006. Opinion of the CONTAM Panel related to ochratoxin A in food. EFSA EFSA-Q-2005-154.
17. Faucet-Marquis V., Pont F., Stormer F.C., Rizk T., Castegnaro M., and Pfohl-Leszkowicz A. Evidence of a new dechlorinated ochratoxin A derivative formed in opossum kidney cell cultures after pretreatment by modulators of glutathione pathways: correlation with DNA-adduct formation. Mol. Nutr. Food Res. 50 6 (2006) 530-542
18. Fink-Gremmels J. Conclusions from the workshops on ochratoxin A in food: recent developments and significance, organized by ILSI Europe in Baden (Austria), 29 June-1 July 2005. Food Addit. Contam. 22 Suppl. 1 (2005) 1-5
19. Fowler L., Everitt J., Stevens J.L., and Jaken S. Redistribution and enhanced protein kinase C-mediated phosphorylation of alpha- and gamma-adducin during renal tumor progression. Cell Growth Differ. 9 5 (1998) 405-413
20. Gagliano N., Donne I.D., Torri C., Migliori M., Grizzi F., Milzani A., Filippi C., Annoni G., Colombo P., Costa F., Ceva-Grimaldi G., Bertelli A.A., Giovannini L., and Gioia M. Early cytotoxic effects of ochratoxin A in rat liver: a morphological, biochemical and molecular study. Toxicology 225 2-3 (2006) 214-224
21. Gekle M., Sauvant C., and Schwerdt G. Ochratoxin A at nanomolar concentrations: a signal modulator in renal cells. Mol. Nutr. Food Res. 49 2 (2005) 118-130
22. Gekle M., Schwerdt G., Freudinger R., Mildenberger S., Wilflingseder D., Pollack V., Dander M., and Schramek H. Ochratoxin A induces JNK activation and apoptosis in MDCK-C7 cells at nanomolar concentrations. J. Pharmacol. Exp. Ther. 293 3 (2000) 837-844
23. Gillman I.G., Clark T.N., and Manderville R.A. Oxidation of ochratoxin A by an Fe-porphyrin system: model for enzymatic activation and DNA cleavage. Chem. Res. Toxicol. 12 11 (1999) 1066-1076
24. Gingras A.C., Gygi S.P., Raught B., Polakiewicz R.D., Abraham R.T., Hoekstra M.F., Aebersold R., and Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13 11 (1999) 1422-1437
25. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelic M., and Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 12129-12134
26. Grosse Y., Chekir-Ghedira L., Huc A., Obrecht-Pflumio S., Dirheimer G., Bacha H., and Pfohl-Leszkowicz A. Retinol, ascorbic acid and alpha-tocopherol prevent DNA adduct formation in mice treated with the mycotoxins ochratoxin A and zearalenone. Cancer Lett. 114 1-2 (1997) 225-229
27. Hong J.T., Lee M.K., Park K.S., Jung K.M., Lee R.D., Jung H.K., Park K.L., Yang K.J., and Chung Y.S. Inhibitory effect of peroxisome proliferator-activated receptor gamma agonist on ochratoxin A-induced cytotoxicity and activation of transcription factors in cultured rat embryonic midbrain cells. J. Toxicol. Environ. Health A 65 5-6 (2002) 407-418
28. Huang Q., Dunn R.T., Jayadev S., DiSorbo O., Pack F.D., Farr S.B., Stoll R.E., and Blanchard K.T. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. 63 2 (2001) 196-207
29. Kaelin Jr. W.G. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J. Am. Soc. Nephrol. 14 11 (2003) 2703-2711
30. Kamp H.G., Eisenbrand G., Schlatter J., Wurth K., and Janzowski C. Ochratoxin A: induction of (oxidative) DNA damage, cytotoxicity and apoptosis in mammalian cell lines and primary cells. Toxicology 206 3 (2005) 413-425
31. Kensler T.W., Curphey T.J., Maxiutenko Y., and Roebuck B.D. Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins. Drug Metab. Drug Interact. 17 1-4 (2000) 3-22
32. Kensler T.W., Wakabayashi N., and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. (2006)
33. Khan S., Martin M., Bartsch H., and Rahimtula A.D. Perturbation of liver microsomal calcium homeostasis by ochratoxin A. Biochem. Pharmacol. 38 1 (1989) 67-72
34. Kim W., and Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13 1 (2003) 55-60
35. Klaunig J.E., and Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 239-267
36. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 9 1 (1999) 40-48
37. Laskin J.D., Heck D.E., and Laskin D.L. The ribotoxic stress response as a potential mechanism for MAP kinase activation in xenobiotic toxicity. Toxicol. Sci. 69 2 (2002) 289-291
38. Lucas B., Grigo K., Erdmann S., Lausen J., Klein-Hitpass L., and Ryffel G.U. HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma. Oncogene 24 42 (2005) 6418-6431
39. Luhe A., Hildebrand H., Bach U., Dingermann T., and Ahr H.J. A new approach to studying ochratoxin A (OTA)-induced nephrotoxicity: expression profiling in vivo and in vitro employing cDNA microarrays. Toxicol. Sci. 73 2 (2003) 315-328
40. Mally A., and Dekant W. DNA adduct formation by ochratoxin A: review of the available evidence. Food Addit. Contam. 22 Suppl. 1 (2005) 65-74
41. Mally A., Pepe G., Ravoori S., Fiore M., Gupta R.C., Dekant W., and Mosesso P. Ochratoxin A causes DNA damage and cytogenetic effects but no DNA adducts in rats. Chem. Res. Toxicol. 18 8 (2005) 1253-1261
42. Mally A., Zepnik H., Wanek P., Eder E., Dingley K., Ihmels H., Volkel W., and Dekant W. Ochratoxin A: lack of formation of covalent DNA adducts. Chem. Res. Toxicol. 17 2 (2004) 234-242
43. Manderville R.A. A case for the genotoxicity of ochratoxin A by bioactivation and covalent DNA adduction. Chem. Res. Toxicol. 18 7 (2005) 1091-1097
44. Manolova Y., Manolov G., Parvanova L., Petkova-Bocharova T., Castegnaro M., and Chernozemsky I.N. Induction of characteristic chromosomal aberrations, particularly X-trisomy, in cultured human lymphocytes treated by ochratoxin A, a mycotoxin implicated in Balkan endemic nephropathy. Mutat. Res. 231 2 (1990) 143-149
45. Mantle P., Kulinskaya E., and Nestler S. Renal tumourigenesis in male rats in response to chronic dietary ochratoxin A. Food Addit. Contam. 22 Suppl. 1 (2005) 58-64
46. Marin-Kuan M., Nestler S., Verguet C., Bezencon C., Piguet D., Mansourian R., Holzwarth J., Grigorov M., Delatour T., Mantle P., Cavin C., and Schilter B. A toxicogenomics approach to identify new plausible epigenetic mechanisms of ochratoxin A carcinogenicity in rat. Toxicol. Sci. 89 1 (2006) 120-134
47. Marin-Kuan M., Nestler S., Verguet C., Bezencon C., Piguet D., Delatour T., Mantle P., Cavin C., and Schilter B. MAPK-ERK activation in kidney of male rats chronically fed ochratoxin A at a dose causing a significant incidence of renal carcinoma. Toxicol. Appl. Pharmacol. 224 (2007) 174-181
48. Misawa H., and Yamaguchi M. Involvement of nuclear factor-1 (NF1) binding motif in the regucalcin gene expression of rat kidney cortex: the expression is suppressed by cisplatin administration. Mol. Cell Biochem. 219 1-2 (2001) 29-37
49. Monnet-Tschudi F., Sorg O., Honegger P., Zurich M.G., Huggett A.C., and Schilter B. Effects of the naturally occurring food mycotoxin ochratoxin A on brain cells in culture. Neurotoxicology 18 3 (1997) 831-839
50. Morooka Y., and Yamaguchi M. Suppressive effect of endogenous regucalcin on deoxyribonuclic acid synthesis in the nuclei of rat renal cortex. Mol. Cell Biochem. 229 1-2 (2002) 157-162
51. Moschos S.J., and Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63 4 (2002) 317-332
52. NTP. Toxicology and carcinogenesis studies of ochratoxin A (CAS No. 303-47-9) in F344/N rats (gavage studies). Natl. Toxicol. Program. Tech. Rep. Ser. 358 (1989) 1-142
53. O'Brien E., and Dietrich D.R. Ochratoxin A: the continuing enigma. Crit. Rev. Toxicol. 35 1 (2005) 33-60
54. Oka H., Chatani Y., Hoshino R., Ogawa O., Kakehi Y., Terachi T., Okada Y., Kawaichi M., Kohno M., and Yoshida O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55 18 (1995) 4182-4187
55. Omar R.F., Gelboin H.V., and Rahimtula A.D. Effect of cytochrome P450 induction on the metabolism and toxicity of ochratoxin A. Biochem. Pharmacol. 51 3 (1996) 207-216
56. Omar R.F., Hasinoff B.B., Mejilla F., and Rahimtula A.D. Mechanism of ochratoxin A stimulated lipid peroxidation. Biochem. Pharmacol. 40 6 (1990) 1183-1191
57. Orlicky D.J. Negative regulatory activity of a prostaglandin F2 alpha receptor associated protein (FPRP). Prostaglandins Leukot. Essent. Fatty Acids 54 4 (1996) 247-259
58. Petrik J., Zanic-Grubisic T., Barisic K., Pepeljnjak S., Radic B., Ferencic Z., and Cepelak I. Apoptosis and oxidative stress induced by ochratoxin A in rat kidney. Arch. Toxicol. 77 12 (2003) 685-693
59. Petroulakis E., and Wang E. Nerve growth factor specifically stimulates translation of eukaryotic elongation factor 1A-1 (eEF1A-1) mRNA by recruitment to polyribosomes in PC12 cells. J. Biol. Chem. 277 21 (2002) 18718-18727
60. Pfohl-Leszkowicz A., and Castegnaro M. Further arguments in favour of direct covalent binding of ochratoxin A (OTA) after metabolic biotransformation. Food Addit. Contam. 22 Suppl. 1 (2005) 75-87
61. Rached E., Pfeiffer E., Dekant W., and Mally A. Ochratoxin A: apoptosis and aberrant exit from mitosis due to perturbation of microtubule dynamics?. Toxicol. Sci. 92 1 (2006) 78-86
62. Rached E., Hard G.C., Blumbach K., Weber K., Draheim R., Lutz W.K., Ozden S., Steger U., Dekant W., and Mally A. Ochratoxin A: 13-week oral toxicity and cell proliferation in male F344/n rats. Toxicol. Sci. 97 (2007) 288-298
63. Ramos-Gomez M., Kwak M.K., Dolan P.M., Itoh K., Yamamoto M., Talalay P., and Kensler T.W. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98 6 (2001) 3410-3415
64. Sauvant C., Holzinger H., and Gekle M. Proximal tubular toxicity of ochratoxin A is amplified by simultaneous inhibition of the extracellular signal-regulated kinases 1/2. J. Pharmacol. Exp. Ther. 313 1 (2005) 234-241
65. Sauvant C., Holzinger H., Mildenberger S., and Gekle M. Exposure to nephrotoxic ochratoxin A enhances collagen secretion in human renal proximal tubular cells. Mol. Nutr. Food Res. 49 1 (2005) 31-37
66. Schaaf G.J., Nijmeijer S.M., Maas R.F., Roestenberg P., de Groene E.M., and Fink-Gremmels J. The role of oxidative stress in the ochratoxin A-mediated toxicity in proximal tubular cells. Biochim. Biophys. Acta 1588 2 (2002) 149-158
67. Schilter B., Marin-Kuan M., Delatour T., Nestler S., Mantle P., and Cavin C. Ochratoxin A: potential epigenetic mechanisms of toxicity and carcinogenicity. Food Addit. Contam. 22 Suppl. 1 (2005) 88-93
68. Schramek H. MAP kinases: from intracellular signals to physiology and disease. News Physiol. Sci. 17 (2002) 62-67
69. Sel S., Ebert T., Ryffel G.U., and Drewes T. Human renal cell carcinogenesis is accompanied by a coordinate loss of the tissue specific transcription factors HNF4 alpha and HNF1 alpha. Cancer Lett. 101 2 (1996) 205-210
70. Sridhar S.S., Hedley D., and Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 4 4 (2005) 677-685
71. Stemmer K., Ellinger-Ziegelbauer H., Ahr H.J., and Dietrich D.R. Carcinogen-specific gene expression profiles in short-term treated Eker and wild-type rats indicative of pathways involved in renal tumorigenesis. Cancer Res. 67 (2007) 4052-4068
72. Takahashi M., Papavero V., Yuhas J., Kort E., Kanayama H.O., Kagawa S., Baxter R.C., Yang X.J., Gray S.G., and Teh B.T. Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int. J. Oncol. 26 4 (2005) 923-931
73. Tessitore L. Apoptosis and cell proliferation are involved in the initiation of liver carcinogenesis by a subnecrogenic dose of diethylnitrosamine in refed rats. J. Nutr. 130 (2000) 104-110
74. Tsurusaki Y., and Yamaguchi M. Overexpression of regucalcin modulates tumor-related gene expression in cloned rat hepatoma H4-II-E cells. J. Cell Biochem. 90 3 (2003) 619-626
75. Tsurusaki Y., and Yamaguchi M. Role of regucalcin in liver nuclear function: binding of regucalcin to nuclear protein or DNA and modulation of tumor-related gene expression. Int. J. Mol. Med. 14 2 (2004) 277-281
76. Turesky R.J. Perspective: ochratoxin A is not a genotoxic carcinogen. Chem. Res. Toxicol. 18 7 (2005) 1082-1090
77. Wen Y.D., Perissi V., Staszewski L.M., Yang W.M., Krones A., Glass C.K., Rosenfeld M.G., and Seto E. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. U.S.A. 97 13 (2000) 7202-7207
78. WHO. Safety Evaluation of Certain Mycotoxins in Food. Fifty-sixth Meeting of the Joint FAO/WHO Expert Committee on Food Additives. WHO Food Additives Series 47 (2001) i-706
79. Xue J.H., Takahashi H., and Yamaguchi M. Stimulatory effect of regucalcin on mitochondrial ATP-dependent calcium uptake activity in rat kidney cortex. J. Cell Biochem. 80 2 (2000) 285-292
80. Yoon H.S., Monks T.J., Everitt J.I., Walker C.L., and Lau S.S. Cell proliferation is insufficient, but loss of tuberin is necessary, for chemically induced nephrocarcinogenicity. Am. J. Physiol. Renal Physiol. 283 2 (2002) F262-F270
81. Yu X., and Kensler T. Nrf2 as a target for cancer chemoprevention. Mutat. Res. 591 1-2 (2005) 93-102
82. Zhang Y., and Gordon G.B. A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway. Mol. Cancer Ther. 3 7 (2004) 885-893